Bayer: Good performance in a challenging environment, Group outlook confirmed

Group sales increase by 1.9 percent (Fx& portfolio adj.) to 9.905 billion euros / EBITDA before special items level year on year at 2.202 billion euros / Business performance at Pharmaceuticals remains strong / Consumer Health with increase in sales (Fx& portfolio adj.), while currency effects weigh on earnings / Crop Science posts substantial rise in sales and earnings due to acquisition– successful start to integration process / Sales and earnings of Animal Health decline following a strong second quarter / One-time gain (before taxes) of roughly 3.9 billion euros from divestments / Net income 2.886 billion euros / Core earnings per share 1.19 euros / Adjusted 2018 Group outlook confirmed
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news